Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports

A Case of Pure Mucinous Breast Carcinoma in a 25-Year-Old Female Who Showed Complete Pathological Response to Neoadjuvant Chemotherapy despite Poor Clinical Response

Introduction

Mucinous breast carcinoma is a rare histologic subtype of primary breast cancers accounting for 1-6%. It is a rare histological variant in young patients and usually presents without lymph node involvement, and its pathological response to neoadjuvant chemotherapy is rarely reported.

Case Presentation

Pure mucinous breast carcinoma in a 25-year-old female was treated with neoadjuvant chemotherapy every 3 weeks for 8 cycles. After the fifth cycle, the mass size showed no change. We performed modified radical mastectomy in the left breast and axillary lymph node clearance. However, the pathological report showed a complete elimination of both the breast tumor and axillary lymph nodes, which were filled with mucus but did not contain malignant cells.

Discussion

Chemotherapy was profoundly effective against the tumor cells, but ineffective against large amounts of extracellular mucus. Even though the cancer cells were sensitive to chemotherapy, the volume of mucinous cancer couldnot be reduced.

Conclusion

In summary, the evaluation criteria of tumor response to chemotherapy based on maximum diameter only should be considered insufficient for mucinous carcinoma.

Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients

Endocrine therapy of breast cancer has been improved continuously during the last decades. Currently, aromatase inhibitors are dominating treatment algorithms for postmenopausal women with hormone-receptor positive breast cancer while tamoxifen still is the most widely used drug for premenopausal women. Several research tools and study designs have been used to challenge established drugs and develop the field of antihormonal therapy. One pivotal study option has been the observation of clinical responses during presurgical/neoadjuvant endocrine therapy (PSET/NET). This strategy has several major advantages. First, the breast tumor, still present in the patient's breast during therapy, can be followed by clinical observations and radiological measurements and any treatment effect will be immediately registered. Second, tumor biopsies may be obtained before initiation and following therapy allowing intra-patient comparisons. These tumor-biopsies may be used for the evaluation of intra-tumor changes associated with drug treatment. As examples, presurgical breast cancer trials have been used to evaluate intra-tumor estrogen levels during therapy with aromatase inhibitors and also to study mechanisms involved in the adaptation processes to estrogen suppression. Biomarker studies have provided information that may be used for patient selection in the future. Finally, recently published results from presurgical trials testing combinations of classical endocrine drugs and novel targeted therapies have produced promising results.

Spatial registration of temporally separated whole breast 3D ultrasound images

The purpose of this study was to evaluate the potential for use of image volume based registration (IVBaR) to aid in measurement of changes in the tumor during chemotherapy of breast cancer. Successful IVBaR could aid in the detection of such changes in response to neoadjuvant chemotherapy and potentially be useful for routine breast cancer screening and diagnosis. IVBaR was employed in a new method of automated estimation of tumor volume in studies following the radiologist identification of the tumor region in the prechemotherapy scan. The authors have also introduced a new semiautomated method for validation of registration based on Doppler ultrasound (U.S.) signals that are independent of the grayscale signals used for registration. This Institutional Review Board approved study was conducted on 10 patients undergoing chemotherapy and 14 patients with a suspicious/unknown mass scheduled to undergo biopsy. Reasonably reproducible mammographic positioning and nearly whole breast U.S. imaging were achieved. The image volume was registered offline with a mutual information cost function and global interpolation based on a thin-plate spline using MIAMI FUSE software developed at the University of Michigan. The success and accuracy of registration of the three dimensional (3D) U.S. image volume were measured by means of mean registration error (MRE). IVBaR was successful with MRE of 4.3 +/- 1.7 mm in 9 out of 10 reproducibility automated breast ultrasound (ABU) studies and in 12 out of 17 ABU image pairs collected before, during, or after 115 +/- 14 days of chemotherapy. Semiautomated tumor volume estimation was performed on registered image volumes giving 86 +/- 8% mean accuracy compared to the radiologist hand-segmented tumor volume on seven cases. Doppler studies yielded fractional volume of color pixels in the region surrounding the lesion and its change with changing breast compression. The Doppler study of patients with detectable blood flow included five patients with suspicious masses and three undergoing chemotherapy. Spatial alignment of the 3D blood vessel data from the Doppler studies provided independent measures for the validation of registration. In 15 Doppler image volume pairs scanned with differing breast compression, the mean centerline separation value was 1.5 +/- 0.6 mm, while MRE based on a few identifiable structural points common to the two grayscale image volumes was 1.1 +/- 0.6 mm. Another measure, the overlap ratio of blood vessels, was shown to increase from 0.32 to 0.59 (+84%) with IVBaR for pairs at various compression levels. These results show that successful registration of ABU scans may be accomplished for comparison and integration of information.

Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy

BACKGROUND

Physical examination (PE), mammography (MG), breast magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (PET), and pathologic evaluation are used to assess primary breast cancer. To the authors' knowledge, their accuracy has not been well studied in patients receiving neoadjuvant chemotherapy. Accuracies of each modality in tumor and lymph node assessment in patients with T3/T4 tumors receiving neoadjuvant chemotherapy were compared.

METHODS

Forty-five patients of a prospective clinical trial studying T3-T4M0 tumors were included. Patients received neoadjuvant chemotherapy: docetaxel/carboplatin with or without trastuzumab before and/or after surgery (depending on HER-2/neu status and randomization). Tumor measurements by PE, MG, and MRI and lymph node status by PE and PET were obtained before and after neoadjuvant chemotherapy. Concordance among different clinical measurements was assessed and compared with the tumor and lymph node staging by pathology. Spearman correlation (r) and root mean square error (RMSE) were used to measure the accuracy of measurements among all modalities and between modalities and pathologic tumor size.

RESULTS

Compared with the tumor size measured by PE, MRI was more accurate than MG at baseline (r=0.559, RMSE=35.4% vs r=0.046, RMSE=66.1%). After neoadjuvant chemotherapy, PE correlated better with pathology than MG or MRI (r=0.655, RMSE=88.6% vs r=0.146, RMSE=147.1% and r=0.364, RMSE=92.6%). Axillary lymph node assessment after neoadjuvant chemotherapy demonstrated high specificity but low sensitivity by PET and PE.

CONCLUSIONS

Findings suggested that MRI was a more accurate imaging study at baseline for T3/T4 tumor, and PE correlated best with pathology finding. PET and PE both correctly predicted positive axillary lymph nodes but not negative lymph nodes.

Clinical application of multidetector row computed tomography in patient with breast cancer

Although multidetector row computed tomography is not the primary method of evaluating breast cancer, it could be performed as an excellent alternative, especially in the presence of magnetic resonance contraindications. Moreover, computed tomography can still have an important role in evaluation of nodal status, thoracic invasion, and distant metastasis because of the large area covered in a single examination. Our experience together with literature indicates that multidetector row computed tomography is a powerful supplementary method for evaluation of patients with breast cancer.

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

BACKGROUND

Neoadjuvant chemotherapy precludes the accurate pre-surgical pathologic measurement of tumor size. The purpose of this study is to review imaging studies performed in patients who received preoperative chemotherapy prior to surgery and determine whether MRI, ultrasound (US) or physical exam best predicted final pathologic tumor size.

METHODS

Stage I, II, and III breast cancer patients were treated with neoadjuvant therapy on trial. As part of the trials, women underwent MRI, US, and physical exam prior to the start of therapy and 1 week after completion of neoadjuvant chemotherapy.

RESULTS

Of the 68 patients with MRI data, the correlation coefficient (r) of MRI to pathologic size of tumor was r = 0.749. Among the 52 patients who had an US assessment the correlation of US to pathology was r = 0.612. Sixty-two patients had physical exam data, and the correlation of examination to pathology size was r = 0.439. MRI correctly predicted 8 of 11 complete responders and accurately evaluated the size of non-responders to neoadjuvant therapy (r = 0.869)

CONCLUSIONS

In a select group of women undergoing neoadjuvant therapy for invasive breast cancer, MRI best predicted pathology response. The use of MRI in neoadjuvant therapy may allow for accurate prediction of patients eligible for breast conservation.

Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy

OBJECTIVE

To assess the accuracy of physical examination, ultrasonography, and mammography in predicting residual size of breast tumors following neoadjuvant chemotherapy.

BACKGROUND

Neoadjuvant chemotherapy is an accepted part of the management of stage II and III breast cancer. Accurate prediction of residual pathologic tumor size after neoadjuvant chemotherapy is critical in guiding surgical therapy. Although physical examination, ultrasonography, and mammography have all been used to predict residual tumor size, there have been conflicting reports about the accuracy of these methods in the neoadjuvant setting.

METHODS

We reviewed the records of 189 patients who participated in 1 of 2 protocols using doxorubicin-containing neoadjuvant chemotherapy, and who had assessment by physical examination, ultrasonography, and/or mammography no more than 60 days before their surgical resection. Size correlations were performed using Spearman rho analysis. Clinical and pathologic measurements were also compared categorically using the weighted kappa statistic.

RESULTS

Size estimates by physical examination, ultrasonography, and mammography were only moderately correlated with residual pathologic tumor size after neoadjuvant chemotherapy (correlation coefficients: 0.42, 0.42, and 0.41, respectively), with an accuracy of +/-1 cm in 66% of patients by physical examination, 75% by ultrasonography, and 70% by mammography. Kappa values (0.24-0.35) indicated poor agreement between clinical and pathologic measurements.

CONCLUSION

Physical examination, ultrasonography, and mammography were only moderately useful for predicting residual pathologic tumor size after neoadjuvant chemotherapy.

A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response

A 30-year-old woman presented with a right breast tumor. Mucinous carcinoma was diagnosed by core needle biopsy (T2: 5 cm N1 M0). Despite receiving a neoadjuvant anthracycline and taxane regimen, the patient demonstrated no clinical response (NC). Based on the patient's strong preference, we performed breast-conserving surgery. On histological examination, we observed widespread mucus and a few viable malignant cells, a Grade 2 therapeutic response. Neither optimal management procedures nor guidelines for chemotherapy for primary mucinous carcinoma of the breast have been established. It is a reasonable assumption, however, that discordance between the clinical response and therapeutic response to neoadjuvant chemotherapy may occur in cases of mucinous carcinoma.